Interventional oncology

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Retrieved on: 
Tuesday, February 27, 2024

TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.

Key Points: 
  • TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
  • At less than 7,700 Lbs and 80 inches high, MAGNETOM Free.Max is the most lightweight, compact whole-body scanner ever offered by Siemens Healthineers.
  • I commend the teams at Siemens Healthineers and Profound as they work to achieve the convergence of their respective diagnostic and interventional MR technologies.
  • We look forward to collaborating with Profound to help expand access to TULSA as well.

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

Retrieved on: 
Monday, January 29, 2024

This year's SIO meeting featured an educational event, Breast Cryoablation Master Class , the first of its kind by a radiology society.

Key Points: 
  • This year's SIO meeting featured an educational event, Breast Cryoablation Master Class , the first of its kind by a radiology society.
  • Interventional oncologists attending the half-day course learned from multidisciplinary experts in breast imaging, breast surgery, interventional radiology, surgical oncology, medical oncology, and radiation oncology.
  • A literature review of notable studies for breast cryoablation was presented, primarily including interim data from IceCure's ICE3 breast cancer cryoablation study, which demonstrated a 96.91% recurrence free rate.
  • Dr. Tomkovich commented, "The Master Class, which was filled to capacity, included interventional oncologists and breast radiologists seeking education to build a successful breast cryoablation program.

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

Retrieved on: 
Tuesday, November 21, 2023

Dr. Diaz-Cartelle brings to Microbot a wealth of experience in the endovascular and interventional space, along with an impressive track record in clinical research.

Key Points: 
  • Dr. Diaz-Cartelle brings to Microbot a wealth of experience in the endovascular and interventional space, along with an impressive track record in clinical research.
  • In this role, he played a pivotal part in the development of global clinical strategy and study oversight, supporting commercial activities and future pipeline development.
  • "We are fortunate to have Dr. Diaz-Cartelle join our team, especially with his extensive experience in the endovascular and interventional space.
  • The Company is grateful for Dr. Morag's vast contribution to the Company over the years and wishes him success in his next ventures.

Canon Medical introduces Alphenix Sky 12 HD interventional system with the new 12”×12” High-Definition (Hi-Def) Detector

Retrieved on: 
Tuesday, September 12, 2023

Tustin California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Tustin, CA, USA, 12th of September 2023 – Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD interventional system with our proprietary high-resolution HD 76 Hi-Def detector.

Key Points: 
  • Tustin California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Tustin, CA, USA, 12th of September 2023 – Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD interventional system with our proprietary high-resolution HD 76 Hi-Def detector.
  • The new Alphenix Sky 12 HD with 12”×12” Hi-Def detector can help improve visualization during Interventional Cardiology (IC), Interventional Neurology (IN), Interventional Oncology (IO), and Interventional Radiology (IR), including pediatric procedures.
  • The Sky 12HD expands the Alphenix family by adding 12”x12” Hi-Def detector to its existing 12”x16” Hi-Def detector.
  • These options now provide clinicians the ideal size for their unique procedural needs, complimenting to the existing lineup of Alphenix Sky+, Alphenix 4D CT, Alphenix Biplane, and Alphenix Core+ systems.

Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, September 5, 2023

LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary patient-centric human extracellular matrix (ECM) platform, today announces the appointment of Christopher (Chris) Stevenson, Ph.D., as Chief Scientific Officer (CSO).

Key Points: 
  • LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary patient-centric human extracellular matrix (ECM) platform, today announces the appointment of Christopher (Chris) Stevenson, Ph.D., as Chief Scientific Officer (CSO).
  • He will also be responsible for leading Engitix’s R&D Pharma partnerships centered on its novel platform technologies.
  • Chris brings to Engitix a strong track record of driving innovation and developing talented teams to propel science into novel therapeutic and diagnostic solutions for patients.
  • Dr Giuseppe Mazza, co-founder and CEO of Engitix, said, “I am delighted to welcome Chris to Engitix at this pivotal time in the company’s development.

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

Retrieved on: 
Monday, July 10, 2023

NBTXR3 is also being evaluated for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for patients with metastatic cancers.

Key Points: 
  • NBTXR3 is also being evaluated for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for patients with metastatic cancers.
  • Under the terms of the license agreement, in collaboration with the Interventional Oncology R&D Unit at Johnson & Johnson, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3.
  • Dial-in information for a conference call Nanobiotix will host to discuss the agreement can be found below.
  • Nanobiotix is eligible for success-based payments of up to $1.8 billion, in the aggregate, relating to potential development, regulatory, and sales milestones.

IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

Retrieved on: 
Thursday, June 15, 2023

The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners

Key Points: 
  • The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners
    The consortium will carry out research into improving clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
    Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the Philips-coordinated IMAGIO consortium [1] of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners [2], to carry out research into less invasive cancer treatments.
  • Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas.
  • In Europe about 2.7 million people are diagnosed with cancer each year [3].
  • This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112053.

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

Retrieved on: 
Tuesday, May 23, 2023

Obsidian Therapeutics Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer.

Key Points: 
  • Obsidian Therapeutics Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer.
  • Before Iovance, he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center, Vanderbilt-Ingram Cancer Center (VICC), where he co-led Translational Research and Interventional Oncology Research Program at VICC.
  • Dr. Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center.
  • Dr. Norkunas is an experienced biotechnology executive, currently serving as Chief Financial Officer at Generation Bio.

IceCure Medical Reports First Quarter 2023 Financial & Operational Results

Retrieved on: 
Monday, May 22, 2023

Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses

Key Points: 
  • Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses
    CAESAREA, Israel, May 22, 2023 /PRNewswire/-- IceCure Medical Ltd. (the "Company" or "IceCure") (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2023 as well as operational and recent corporate developments.
  • We believe this momentum in the market is bolstered by a broader trend toward minimally invasive procedures," stated IceCure CEO Eyal Shamir.
  • Company's Ordinary Shares to Trade Exclusively on Nasdaq: IceCure announced its voluntary delisting from the Tel Aviv Stock Exchange ("TASE").
  • In the first quarter of 2023, sales increased in the U.S. and Europe relative to the same quarter last year.

Advancing Precision Care: GE HealthCare Introduces an Innovative Solution to Help Expand Interventional CT Access

Retrieved on: 
Tuesday, April 18, 2023

Interventional radiology – and specifically interventional CT – plays a key role in the diagnosis and treatment of disease.

Key Points: 
  • Interventional radiology – and specifically interventional CT – plays a key role in the diagnosis and treatment of disease.
  • Instead of working wholly within the CT system’s narrow bore, interventionalists using CT-Navigation can simply place a sensor on the patient inside the gantry.
  • Today, the innovative solution focuses solely on CT applications, but GE HealthCare plans to expand the technology to its image guided therapy (IGT) business in the near future – further advancing its clinical application and reach.
  • Additionally, GE HealthCare is showcasing CT-Navigation at the European Conference on Interventional Oncology (ECIO) in Stockholm, Sweden.